(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.21%.
Solid Biosciences's earnings in 2025 is -$167,135,000.On average, 15 Wall Street analysts forecast SLDB's earnings for 2025 to be -$158,726,530, with the lowest SLDB earnings forecast at -$213,863,606, and the highest SLDB earnings forecast at -$143,323,676. On average, 14 Wall Street analysts forecast SLDB's earnings for 2026 to be -$154,542,750, with the lowest SLDB earnings forecast at -$204,927,302, and the highest SLDB earnings forecast at -$109,619,706.
In 2027, SLDB is forecast to generate -$138,119,272 in earnings, with the lowest earnings forecast at -$191,947,456 and the highest earnings forecast at -$114,528,051.